Bristol Myers Squibb™

Investigational Trial of Iberdomide (CC-220) in Patients With Relapsed or Refractory Lymphomas

CC-220-NHL-001

A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of Iberdomide (CC-220), Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas[1]

Enrolling in the US and EU ***NCT04464798 Phase 1/2***

PRIMARY ENDPOINTS
Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)

SELECT SECONDARY ENDPOINTS
AEs; pharmacokinetics; ORR, CRR, TTR, and DoR; PFS; and OS

KEY ELIGIBILITY CRITERIA

- R/R lymphoma
- ECOG PS ≤2
- ANC ≥1.5 x 10^9/L or ≥1.0 x 10^9/L
- Hemoglobin ≥8 g/dL
- Platelets ≥75 x 10^9/L or ≥50 x 10^9/L
- AST/ALT ≤2.5 x ULN
- Serum total bilirubin ≤1.5 x ULN (except in cases of Gilbert's syndrome, then ≤3.0 x ULN)
- Estimated CrCl ≥50 mL/min

TREATMENT* *Estimated N=152*

- **Cohort A:** iberdomide (CC-220) monotherapy — *R/R lymphoma*
- **Cohort B:** iberdomide (CC-220) + rituximab — *R/R B-cell lymphoma*
- **Cohort C:** iberdomide (CC-220) + obinutuzumab — *R/R FL (1-3a) and MZL*
- **Cohort D:** iberdomide (CC-220) monotherapy — *Other lymphoma*
- **Cohort E:** iberdomide (CC-220) + rituximab — *Aggressive B-cell lymphoma*
- **Cohort F:** iberdomide (CC-220) + rituximab — *FL (1-3a) and MZL*
- **Cohort G:** iberdomide (CC-220) + obinutuzumab — *FL (1-3a) and MZL*

FOLLOW-UP

Safety
From first dose to 28 days after last patient discontinues study treatment

Efficacy

****Up to progressive disease or 12 cycles for patients with FL or MZL, and up to progressive disease or 24 cycles for all other patients with lymphoma.***

CONTACT: ClinicalTrialDisclosure@bms.com

The safety and efficacy of iberdomide (CC-220) and/or its uses are under investigation and have not been established.
There is no guarantee that iberdomide (CC-220) will receive health authority approval or become commercially available in any country for the uses being investigated.

AE, adverse event; **ALT**, alanine aminotransferase; **ANC**, absolute neutrophil count; **AST**, aspartate aminotransferase; **CRR**, complete response rate; **CrCl**, creatinine clearance; **DoR**, duration of response; **ECOG PS**, Eastern Cooperative Oncology Group performance status; **FL**, follicular lymphoma; **MZL**, marginal zone lymphoma; **ORR**, objective response rate; **OS**, overall survival; **PFS**, progression-free survival; **R/R**, relapsed/refractory; **TTR**, time to response; **ULN**, upper limit of normal.

1. ClinicalTrials.gov. NCT04464798. Accessed May 13, 2021.